subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	PHS criteria and bupivacaine consumption	12499	12607	PHS criteria and bupivacaine consumption in SPCA group was significantly lower than in SIA group. (Table 2).
subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	VAS mean score at 16 h	12233	12361	VAS mean score at 16 h after the first SP instillation of bupivacaine 0.5% in SPCA group was significantly reduced to SIA group.
subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	the incidence of adverse effects, such as pneumonia, atelectasis, bronchoscopic interventions, reintubations, hypersensitivity and postoperative ICU and hospital stay	11110	11358	there were no significant differences between the SP-treatment groups comparing the incidence of adverse effects, such as pneumonia, atelectasis, bronchoscopic interventions, reintubations, hypersensitivity and postoperative ICU and hospital stay (
subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	VAS scores for 24 hr	11895	12071	When VAS scores were analyzed duration 24h, there were also no differences between the groups. There weren't any differences between sex and VAS scores at three times. (p<0.05)
subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	PHS criteria and bupivacaine consumption	12363	12607	Supplemental opioid demand, PHS criteria and bupivacaine consumption were statistically significant, as, rate of IV opioid consumption, PHS criteria and bupivacaine consumption in SPCA group was significantly lower than in SIA group. (Table 2).
subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	mean pain scores at 8 and 24h	11740	11894	However, there was no difference between the groups when comparing mean pain scores at 8 and 24h the first SP instillation of bupivacaine 0.5% (Figure 1).
subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	the incidence of adverse effects, such as pneumonia, atelectasis, bronchoscopic interventions, reintubations, hypersensitivity and postoperative ICU and hospital stay	11110	11366	there were no significant differences between the SP-treatment groups comparing the incidence of adverse effects, such as pneumonia, atelectasis, bronchoscopic interventions, reintubations, hypersensitivity and postoperative ICU and hospital stay (Table 1)
subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	mean pain scores at 8 and 24h	1595	1917	Although pain scores were significantly reduced at 16 hours after the first subpleural instillation of bupivacaine 0.5% with patient-controlled analgesia, comparison between mean pain scores in the two groups at 8 and 24 hours after the first subpleural instillation of bupivacaine 0.5% revealed no significant difference.
subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine)	subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine)	VAS scores for 24 hr	1931	2021	no significant difference was found in VAS scores at the three evaluated times (p < 0.05).
